| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ba446698ce1211491b2e89b8c02b6124 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-72 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-303
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 |
| filingDate |
2005-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2012-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4b787ce7a57dcff73e474a84cbc5dee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6a5f1705fecb1c31c0039276db10268
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_baf72b2a83c1b22575481d9b71cd7fdd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c59737325bd695684d24a0d43b6f62a4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a87f781c196c9ea4f533cc5889cc261
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_159296a3b495ccdac37a32143869f4e5 |
| publicationDate |
2012-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2451030-C2 |
| titleOfInvention |
Anti-glypican 3-antibody having modified sugar chain |
| abstract |
FIELD: medicine. n SUBSTANCE: there are described versions of compositions of human glypican 3 IgGl antibodies. Each composition contains a mixture of human glypican 3 antibodies in an effective amount. The mixture consists of the antibodies of standard structure and either more than 20 % of the fucose-free antibodies, or the antibodies having bisectional N-acetylglucosamide. Each antibody is characterised by a certain amino acid sequence. One version of the composition provides the antibody containing three CDR light and three CDR heavy chains. According to the other version, each antibody is characterised by the presence of variable areas of heavy and light chains. There are described versions of the method for preparing glypican 3 antibody with using a cell with the reduced ability of fucose attachment to sugar chains into which the gene coding the antibody from the composition is introduced. What is offered is an anticancer drug on the basis of the antibody composition. n EFFECT: using the invention provides higher ADCC cytotoxic activity that can find application in cancer therapy. n 10 cl, 7 dwg, 2 tbl, 9 ex |
| priorityDate |
2004-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |